Folate and cancer: Epidemiological perspective

Folate in Health and Disease, Second Edition

Volumn , Issue , 2009, Pages 205-233

  Chen, Jia ^a   Xu, Xinran ^a   Liu, Amy ^b   Ulrich, Cornelia M ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956324727     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (149)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59.
2. Ulrich CM, Curtin K, Samowitz W, Bigler J, Potter JD, Caan B, Slattery ML. MTHFR variants reduce the risk of G:C^A:T transition mutations within the p53 tumor suppressor gene in colon tumors. JNutr 2005; 135:2462-67.
3. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000; 9:849-53.
4. Combs GF. The Vitamins: Fundamental Aspects in Nutrition and Health. San Diego, CA: Academic Press, 1992.
5. Machlin LJ. Handbook of Vitamins, 2nd ed., revised and expanded ed. New York: M. Dekker, 1991.
6. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: A meta-analytical approach. Int J Cancer 2005; 113:825-28.
7. Sauberlich HE, Kretsch MJ, Skala JH, Johnson HL, Taylor PC. Folate requirement and metabolism in nonpregnant women. Am J Clin Nutr 1987; 46:1016-28.
8. Hannon-Fletcher MP, Armstrong NC, Scott JM, Pentieva K, Bradbury I, Ward M, Strain JJ, et al. Determining bioavailability of food folates in a controlled intervention study. Am J Clin Nutr 2004; 80:911-18.
9. Larsson SC, Giovannucci E, Wolk A. A prospective study of dietary folate intake and risk of colorectal cancer: Modification by caffeine intake and cigarette smoking. Cancer Epidemiol Biomarkers Prev 2005; 14:740-43.
10. Zhang SM, Moore SC, Lin J, Cook NR, Manson JE, Lee I, Buring JE. Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women. Am J Epidemiol2006; 163:108-15.
11. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57:1098-102.
12. Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Stenling R, Riboli E, Winkvist A, Palmqvist R. Low folate levels may protect against colorectal cancer. Gut 2006; 55:1461-66.
13. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: A meta-analysis.J Natl Cancer Inst 2007; 99:64-76.
14. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE, Willett WC. A prospective study of folate intake and the risk of breast cancer. JAMA1999; 281:1632-37.
15. Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, Vachon CM, Olson JE, Therneau TM, Folsom AR. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 2001; 12:420-28.
16. Rohan TE, Jain MG, Howe GR, Miller AB. Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 2000; 92:266-69.
17. Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst2006; 98:1607-22.
18. Lajous M, Romieu I, Sabia S, Boutron-Ruault MC, Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women. Cancer Causes Control 2006; 17:1209-13.
19. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG. Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr 2006; 83:895-904.
20. Cho E, Holmes M, Hankinson SE, Willett WC. Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. Cancer Epidemiol Biomarkers Prev 2007; 16:2787-90.
21. Ericson U, Sonestedt E, Gullberg B, Olsson H, Wirfalt E. High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmo diet and cancer cohort. Am J Clin Nutr 2007; 86:434-43.
22. Ulrich CM. Folate and cancer prevention: A closer look at a complex picture. Am J Clin Nutr 2007; 86:271-73.
23. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: A meta-analysis. Gastroenterology 2006; 131: 1271-83.
24. Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, et al. The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydro-folate reductase polymorphisms in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16:2416-24.
25. Cho E, Hunter DJ, Spiegelman D, Albanes D, Beeson WL, van den Brandt PA, Colditz GA, et al. Intakes of vitamins A, C and E and folate and multivitamins and lung cancer: A pooled analysis of 8 prospective studies. Int J Cancer 2006; 118:970-78.
26. Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med 2008; 177:524-30.
27. Stolzenberg-Solomon RZ, Albanes D, Nieto FJ, Hartman TJ, Tangrea JA, Rautalahti M, Sehlub J, Virtamo J, Taylor PR. Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. J Natl Cancer Inst 1999; 91:535-41.
28. Schernhammer E, Wolpin B, Rifai N, Cochrane B, Manson JA, Ma J, Giovannucci E, Thomson C, Stampfer MJ, Fuchs C. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res 2007; 67:5553-60.
29. Navarro Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Dietary folate consumption and risk of ovarian cancer: A prospective cohort study. Eur J Cancer Prev2006; 15:511-15.
30. Tworoger SS, Hecht JL, Giovannucci E, Hankinson SE. Intake of folate and related nutrients in relation to risk of epithelial ovarian cancer. Am J Epidemiol 2006; 163:1101-11.
31. Kelemen LE, Sellers TA, Vierkant RA, Harnack L, Cerhan JR. Association of folate and alcohol with risk of ovarian cancer in a prospective study of postmenopausal women. Cancer Causes Control 2004; 15:1085-93.
32. Larsson SC, Giovannucci E, Wolk A. Dietary folate intake and incidence of ovarian cancer: The Swedish mammography cohort. J Natl Cancer Inst 2004; 96:396-402.
33. Welzel TM, Katki HA, Sakoda LC, Evans AA, London WT, Chen G, O’Broin S, Shen F, Lin W, McGlynn KA. Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:1279-82.
34. Lim U, Weinstein S, Albanes D, Pietinen P, Teerenhovi L, Taylor PR, Virtamo J, Stolzenberg-Solomon R. Dietary factors of one-carbon metabolism in relation to non-Hodgkin lymphoma and multiple myeloma in a cohort of male smokers. Cancer Epidemiol Biomarkers Prev 2006; 15:1109-14.
35. Zhang SM, Hunter DJ, Rosner BA, Giovannucci EL, Colditz GA, Speizer FE, Willett WC. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin’s lymphoma among women. Cancer Epidemiol Biomarkers Prev 2000; 9:477-85.
36. Koutros S, Zhang Y, Zhu Y, Mayne ST, Zahm SH, Holford TR, Leaderer BP, Boyle P, Zheng T. Nutrients contributing to one-carbon metabolism and risk of non-Hodgkin lymphoma subtypes. Am J Epidemiol 2008; 167:287-94.
37. Lim U, Schenk M, Kelemen LE, Davis S, Cozen W, Hartge P, Ward MH, StolzenbergSolomon R. Dietary determinants of one-carbon metabolism and the risk of non-Hodgkin’s lymphoma: NCI-SEER case-control study, 1998-2000. Am JEpidemiol 2005; 162:953-64.
38. Polesel J, Dal Maso L, La Vecchia C, Montella M, Spina M, Crispo A, Talamini R, Franceschi S. Dietary folate, alcohol consumption, and risk of non-Hodgkin lymphoma. Nutr Cancer 2007; 57:146-50.
39. Wang JT, Ma XC, Cheng YY, Ding L, Zhou Q. A case-control study on the association between folate and cervical cancer. Zhonghua Liu Xing Bing Xue Za Zhi 2006; 27:424-27.
40. VanEenwyk J, Davis FG, Bowen PE. Dietary and serum carotenoids and cervical intraepithelial neoplasia. Int J Cancer 1991; 48:34-38.
41. Ziegler RG, Jones CJ, Brinton LA, Norman SA, Mallin K, Levine RS, Lehman HF, Hamman RF, Trumble AC, Rosenthal JF. Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Causes Control 1991; 2:17-29.
42. Liu T, Soong S, Wilson N, Craig C, Cole P, Macaluso M, Butterworth C Jr. A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol Biomarkers Prev1993; 2:525-30.
43. Kwasniewska A, Charzewska J, Tukendorf A, Semczuk M. Dietary factors in women with dysplasia colli uteri associated with human papillomavirus infection. Nutr Cancer1998; 30:39-45.
44. Brock KE, Berry G, Mock PA, MacLennan R, Truswell AS, Brinton LA. Nutrients in diet and plasma and risk of in situ cervical cancer. J Natl Cancer Inst 1988; 80:580-85.
45. Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L, Goodman MT. Diet and premalignant lesions of the cervix: Evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control 2003; 14:859-70.
46. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer2000; 82:1332-38.
47. Thomson SW, Heimburger DC, Cornwell PE, Turner ME, Sauberlich HE, Fox LM, Butterworth CE. Correlates of total plasma homocysteine: Folic acid, copper, and cervical dysplasia. Nutrition 2000; 16:411-16.
48. Piyathilake CJ, Macaluso M, Brill I, Heimburger DC, Partridge EE. Lower red blood cell folate enhances the HPV-16-associated risk of cervical intraepithelial neoplasia. Nutrition 2007; 23:203-10.
49. Butterworth CE Jr, Hatch KD, Macaluso M, Cole P, Sauberlich HE, Soong SJ, Borst M, Baker W. Folate deficiency and cervical dysplasia. JAMA 1992; 267:528-33.
50. Potischman N, Brinton LA, Laiming VA, Reeves WC, Brenes MM, Herrero R, Tenorio F, de Britton RC, Gaitan E. A case-control study of serum folate levels and invasive cervical cancer. Cancer Res 1991; 51:4785-89.
51. Yeo AS, Schiff MA, Montoya G, Masuk M, van Asselt-King L, Becker TM. Serum micronutrients and cervical dysplasia in southwestern American Indian women. Nutr Cancer 2000; 38:141-50.
52. Weinstein SJ, Ziegler RG, Frongillo EA Jr, Colman N, Sauberlich HE, Brinton LA, Hamman RF, et al. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U.S. women. J Nutr 2001; 131:2040-48.
53. Ziegler RG, Weinstein SJ, Fears TR. Nutritional and genetic inefficiencies in one-carbon metabolism and cervical cancer risk. J Nutr 2002; 132:2345S-49.
54. Butterworth C Jr, Hatch K, Gore H, Mueller H, Krumdieck C. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 1982; 35:73-82.
55. Butterworth CE Jr, Hatch KD, Soong SJ, Cole P, Tamura T, Sauberlich HE, Borst M, Macaluso M, Baker V. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am J Obstet Gynecol 1992; 166:803-09.
56. Childers J, Chu J, Voigt L, Feigl P, Tamimi H, Franklin E, Alberts D, Meyskens F Jr. Chemoprevention of cervical cancer with folic acid: A phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 1995; 4:155-59.
57. Zarcone R, Bellini P, Carfora E, Vicinanza G, Raucci F. Folic acid and cervix dysplasia. Minerva Ginecol 1996; 48:397-400.
58. Thompson JR, Gerald PF, Willoughby ML, Armstrong BK. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: A case-control study. Lancet 2001; 358:1935-40.
59. Dockerty JD, Herbison P, Skegg DC, Elwood M. Vitamin and mineral supplements in pregnancy and the risk of childhood acute lymphoblastic leukaemia: A case-control study. BMC Public Health 2007; 7:136.
60. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B, Maurizi M. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer 2005; 103:284-92.
61. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, Ferekidis E, Kandiloros D. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res 2006; 26(3B):2345-48.
62. Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, Saito T, Sato S, Ueda R, Tajima K. One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: Case-control study. Cancer Sci 2007; 98:1439-46.
63. Xu W, Shrubsole MJ, Xiang Y, Cai Q, Zhao G, Ruan Z, Cheng J, Zheng W, Shu XO. Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2007; 16:281-87.
64. McCann SE, Freudenheim JL, Marshall JR, Brasure JR, Swanson MK, Graham S. Diet in the epidemiology of endometrial cancer in western New York (United States). Cancer Causes Control 2000; 11:965-74.
65. Negri E, La Vecchia C, Franceschi S, Levi F, Parazzini F. Intake of selected micronutrients and the risk of endometrial carcinoma. Cancer 1996; 77:917-23.
66. Potischman N, Swanson CA, Brinton LA, McAdams M, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Hoover RN. Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control 1993; 4:239-50.
67. Nijhout HF, Reed MC, Budu P, Ulrich CM. A mathematical model of the folate cycle: New insights into folate homeostasis. J Biol Chem 2004; 279:55008-16.
68. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94:3290-95.
69. Luebeck EG, Moolgavkar SH, Liu AY, Boynton A, Ulrich CM. Does folic acid supplementation prevent or promote colorectal cancer? Results from model-based predictions. Cancer Epidemiol Biomarkers Prev 2008; 7:1360-67.
70. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med 2004; 229:988-95.
71. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet1995; 10:111-13.
72. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A^C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis2001; 156:409-15.
73. Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC, Teitelbaum SL, etal. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Cancer Res 2005; 65:1606-14.
74. Bailey LB, Gregory JF 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr1999; 129:919-22.
75. Ulvik A, Ueland PM, Fredriksen A, Meyer K, Vollset SE, Hoff G, Schneede J. Functional inference of the methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms from a large-scale epidemiological study. Hum Genet 2007; 121:57-64.
76. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS, Franco RF. 5,10-methyl-enetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1956-63.
77. Zintzaras E, Koufakis T, Ziakas PD, Rodopoulou P, Giannouli S, Voulgarelis M. A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol 2006; 21:501-10.
78. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S. Role in translation of a triple tandemly repeated sequence in the 5’-untranslated region of human thymidylate synthase mRNA. Nucl Acids Res 1987; 15:1259-70.
79. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-97.
80. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70.
81. Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J, Ma J. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:958-62.
82. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:2509-16.
83. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA, Morgan GJ. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood2002; 99:3786-91.
84. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14:319-27.
85. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002; 62:3361-64.
86. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, Hunter DJ. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001; 154:667-72.
87. Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, Peng K, Shane B, Evans AE, Whitehead AS. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17:298-309.
88. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, Willett WC, et al. A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:825-29.
89. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C^T and methionine synthase 2756A^G polymorphisms: A study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004; 13:2175-80.
90. Lissowska J, Gaudet MM, Brinton LA, Chanock SJ, Peplonska B, Welch R, Zatonski W, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: A population-based case-control study and meta-analyses. Int J Cancer 2007; 120:2696-703.
91. Shrubsole MJ, Gao Y, Cai Q, Shu XO, Dai Q, Jin F, Zheng W. MTR and MTRR polymorphisms, dietary intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev2006; 15:586-88.
92. Xu X, Gammon MD, Zhang H, Wetmur JG, Rao M, Teitelbaum SL, Britton JA, Neugut AI, Santella RM, Chen J. Polymorphisms of one-carbon metabolizing genes and risk of breast cancer in a population-based study. Carcinogenesis 2007; 28:1504-09.
93. Justenhoven C, Hamann U, Pierl CB, Rabstein S, Pesch B, Harth V, Baisch C, et al.One-carbon metabolism and breast cancer risk: No association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Biomarkers Prev 2005; 14:3015-18.
94. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev2004; 13:157-62.
95. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67:317-23.
96. Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, Evans A, Whitehead AS. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis2001; 157:451-56.
97. Jacques PF, Bostom AG, Selhub J, Rich S, Ellison RC, Eckfeldt JH, Gravel RA, Rozen R, National Heart, Lung and Blood Institute, National Institutes of Health. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI family heart study. Atherosclerosis 2003; 166:49-55.
98. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002; 13:239-48.
99. Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J, Natsukawa S, Shaura K, et al. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. Nutr Cancer 2005; 53:42-50.
100. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): A risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A 2004; 124:339-45.
101. Xu X, Gammon MD, Wetmur JG, Rao M, Gaudet MM, Teitelbaum SL, Britton JA, Neugut AI, Santella RM, Chen J. A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr 2007; 85:1098-102.
102. Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H, Zhang J. Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of northern China. Cancer Causes Control 2007; 18:143-52.
103. Kelemen LE, Sellers TA, Schildkraut JM, Cunningham JM, Vierkant RA, Pankratz VS, Fredericksen ZS, et al. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 2008; 68:2498-506.
104. Wang L, Lu J, An J, Shi Q, Spitz MR, Wei Q. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: A case-control analysis. Lung Cancer2007; 57:143-51.
105. Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, Giovannucci EL, Hunter DJ. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev2006;15:2408-17.
106. Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Feigelson HS, Thun MJ, Calle EE. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 2007; 16:1140-47.
107. Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ. Twenty-four nonsynonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses’ Health Study. Carcinogenesis 2007; 28:1510-19.
108. Ulrich CM, Nijhout HF, Reed MC. Mathematical modeling: Epidemiology meets systems biology. Cancer Epidemiol Biomarkers Prev 2006; 15:827-29.
109. Reed MC, Nijhout HF, Neuhouser ML, Gregory JF III, Shane B, James SJ, Boynton A, Ulrich CM. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. JNutr 2006; 136:2653-61.
110. Nijhout HF, Reed MC, Anderson DF, Mattingly JC, James SJ, Ulrich CM. Long-range allosteric interactions between the folate and methionine cycles stabilize DNA methyla-tion reaction rate. Epigenetics 2006; 1:81-87.
111. Nijhout HF, Reed M, Lam S, Shane B, Gregory J, Ulrich C. In silico experimentation with a model of hepatic mitochondrial folate metabolism. Theor Biol Med Model 2006; 3:40.
112. Chabner B. Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed., Philadelphia: Lippincott-Raven Publishers, 2001.
113. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001; 61:857-65.
114. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431-57.
115. Robien K. Folate during antifolate chemotherapy: What we know… and do not know. Nutr Clin Pract 2005; 20:411-22.
116. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: Post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52:3030-38.
117. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, Kremer J. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross-sectional observational study. Ann Rheum Dis 2005; 64:1180-85.
118. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: A randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154:1169-74.
119. Takacs P, Rodriguez L. High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet 2005; 89:301-02.
120. Borsi JD, Wesenberg F, Stokland T, Moe PJ. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 1991; 27:1006-09.
121. Browman G, Goodyear M, Levine M, Russell R, Archibald S, Young J. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: A randomized placebo-controlled clinical trial. J Clin Oncol 1990; 8:203-08.
122. Branda RF, Naud SJ, Brooks EM, Chen Z, Muss H. Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy-induced mucositis and neutropenia. Cancer 2004; 101:1058-64.
123. Sellers TA, Alberts SR, Vierkant RA, Grabrick DM, Cerhan JR, Vachon CM, Olson JE, Kushi LH, Potter JD. High-folate diets and breast cancer survival in a prospective cohort study. Nutr Cancer 2002; 44:139-44.
124. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID. Commentary: A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007; 12:808-15.
125. Hooijberg JH, de Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: Therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006; 58:1-12.
126. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: Polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3:912-20.
127. Robien K, Boynton A, Ulrich CM. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005; 6:673-89.
128. Bell KN, Oakley GP Jr. Tracking the prevention of folic acid-preventable spina bifida and anencephaly. Birth Defects Res A Clin Mol Teratol 2006; 76:654-57.
129. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: Judging causality in the face of inconclusive trial evidence. BMJ 2006; 333:1114-17.
130. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr2007; 86:1563S-68.
131. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007; 369:1876-82.
132. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 2007; 369:208-16.
133. Kim Y. Role of folate in colon cancer development and progression. J Nutr2003;133:3731S-39.
134. Song J, Medline A, Mason JB, Gallinger S, Kim Y. Effects of dietary folate on intestinal tumorigenesis in the ApcMin mouse. Cancer Res 2000; 60:5434-40.
135. McKay JA, Williams EA, Mathers JC. Gender-specific modulation of tumorigene-sis by folic acid supply in the apc mouse during early neonatal life. Br J Nutr 2008; 99:550-58.
136. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: A hypothesis. Cancer Epidemiol Biomarkers Prev 2007; 16:1325-29.
137. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, et al. Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. JAMA 2007; 297:2351-59.
138. Ulrich CM, Potter JD. Folate and cancer—Timing is everything. JAMA 2007; 297:2408-09.
139. Jaszewski R, Misra S, Tobi M, Ullah N, Naumoff JA, Kucuk O, Levi E, Axelrod BN, Patel BB, Majumdar AP. Folic acid supplementation inhibits recurrence of colorectal adenomas: A randomized chemoprevention trial. World J Gastroenterol 2008; 14:4492-98.
140. Baggott JE, Vaughn WH, Juliana MM, Eto I, Krumdieck CL, Grubbs CJ. Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors. J Natl Cancer Inst 1992; 84:1740-44.
141. Kotsopoulos J, Sohn K, Martin R, Choi M, Renlund R, Mckerlie C, Hwang SW, Medline A, Kim YJ. Dietary folate deficiency suppresses A-methyl-A-nitrosourea-induced mammary tumorigenesis in rats. Carcinogenesis 2003; 24:937-44.
142. Kotsopoulos J, Medline A, Renlund R, Sohn K, Martin R, Hwang SW, Lu S, Archer MC, Kim Y. Effects of dietary folate on the development and progression of mammary tumors in rats. Carcinogenesis 2005; 26:1603-12.
143. Charles D, Ness AR, Campbell D, Davey Smith G, Hall MH. Taking folate in pregnancy and risk of maternal breast cancer. BMJ 2004; 329:1375-76.
144. Huang Y, Han S, Li Y, Mao Y, Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: A meta-analysis. J Hum Genet 2007; 52:73-85.
145. Hubner RA, Houlston RS. MTHFR C677T and colorectal cancer risk: A meta-analysis of 25 populations. Int J Cancer 2007; 120:1027-35.
146. Zintzaras E. Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: A meta-analysis. Clin Genet 2006; 69:327-36.
147. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: A meta-analysis. J Hum Genet 2008; 53:340-48.
148. Boccia S, Hung R, Ricciardi G, Gianfagna F, Ebert MPA, Fang J, Gao C, et al. Meta-and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: A huge-GSEC review. Am J Epidemiol 2008; 167:505-16.
149. Zintzaras E. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: A meta-analysis. J Hum Genet2006; 51:618-24.